Navigation Links
Regulus Demonstrates Initial Progress in microRNA Biomarkers MS Collaboration and Receives Milestone Payment from Biogen Idec
Date:11/20/2013

#160;

In August 2012, Regulus entered into a research collaboration with Biogen Idec to explore microRNAs as biomarkers for disease monitoring and response to therapy. In June 2013, Regulus and Biogen Idec amended the collaboration agreement to update the research plan and criteria for success. The collaboration is initially focused on the discovery of microRNAs as biomarkers for MS. Under the transaction, Regulus has received an upfront payment and has earned an initial milestone payment and is also eligible to receive additional milestone payments. Additionally, Biogen Idec made an investment in Regulus in the form of a promissory note that converted into shares of Regulus' common stock upon the closing of the Company's initial public offering in October 2012.

About microRNAs and microRNAs as Biomarkers

The discovery of microRNAs in humans during the last decade is one of the most exciting scientific breakthroughs in recent history. microRNAs are small RNA molecules, typically 20 to 25 nucleotides in length, that do not encode proteins but instead regulate gene expression. More than 500 microRNAs have been identified in the human genome, and over one-third of all human genes are believed to be regulated by microRNAs. microRNA expression, or function, has been shown to be significantly altered or dysregulated in many disease states, including oncology, fibrosis and metabolic diseases. Regulus believes that microRNAs are clinically relevant therapeutic targets and may be ideally suited as biomarkers for these disease states and others, like MS. 

microRNAs have been detected in bodily fluids such as blood, and emerging data has demonstrated that microRNA signatures in blood can mimic the expression profile observed in disease tissues. Regulus has a comprehensive intellectual property estate and oligonucleotide technology know-how and believes that microRNA
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology news :

1. Study demonstrates cells can acquire new functions through transcriptional regulatory network
2. New study demonstrates the role of urban greenery in CO2 exchange
3. WALTHAM® demonstrates commitment to scientific dialogue and exchange at international human animal interaction conference
4. Published clinical trial demonstrates efficacy of Sea-Band® for migraine-related nausea
5. University of Toronto study demonstrates impact of adversity on early life development
6. UT Arlington physics team demonstrates new power generation technique
7. First-in-man study demonstrates the therapeutic effect of RNAi gene silencing in cancer treatment
8. Genetic study of house dust mites demonstrates reversible evolution
9. Rotavirus vaccine developed in India demonstrates strong efficacy
10. Fingerprint Cards (FPC) Demonstrates Fingerprint Biometric Touch Sensor for Microsoft Windows 8.1
11. Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ... some long-held beliefs about the condition and the best ways ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader ... is seeing a staggering demand from its licensees for ... Company revealed, is not solely coming from fitness and ... well. "A wearable is only as useful ... accuracy is the ultimate driver in long-term mass consumer ...
(Date:12/10/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ) ... Market in Japan 2014-2018" report to their ... The integration of biometrics and smart ... upgradation of the driver,s license is one of ... the aforementioned projects, biometrics is being used as ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... an extraordinary ability to remember numerals that is superior ... December 4th issue of Current Biology, a publication of ... many biologists, who believe that humans are superior to ... Kyoto University. No one can imagine that chimpanzeesyoung chimpanzees ...
... sizes. Each cell is shaped in such a way as ... wrong and a cell does not adopt its dedicated shape, ... problems in the body. Researchers at the European Molecular Biology ... (AMOLF), The Netherlands, have now decoded a molecular mechanism that ...
... published today in Nature Genetics shows that some rearrangements ... thought. The work is likely to lead to new ... diagnosis of genomic disease. The scientists from the ... in the genome where rearrangements cause genetic diseases, so-called ...
Cached Biology News:Young chimps top adult humans in numerical memory 2How cells keep in shape 2Mutant sperm guide clinicians to new diseases 2Mutant sperm guide clinicians to new diseases 3
(Date:12/24/2014)... , Dec. 23, 2014 China ... the "Company"), a leading fully integrated plasma-based biopharmaceutical ... announced that its majority-owned subsidiary, Shandong Taibang Biological ... ("GMP") certification from the China Food and Drug ... production facility. As previously disclosed in the Company,s ...
(Date:12/24/2014)... SARASOTA, Fla. , Dec. 23, 2014  Rock ... today that it has filed a Clinical Trial Application ... Medicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval ... its lead molecule, Anatabine Citrate. Contingent on ... to conduct a Phase I trial to assess the ...
(Date:12/22/2014)... /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: ... the development of autologous cell therapies, announced today the ... Calgary in conjunction with co-authors from Kyoto University and ... company,s ongoing clinical research using dermal sheath cup (DSC) ... The paper entitled " Hair Follicle Dermal Stem ...
(Date:12/22/2014)... December 22, 2014 The ... publication of original research, reviews and editorials addressing ... clinical practice, today published a provocative article exploring ... development, progression and potential treatment of prostate cancer. ... research and proposes the possibility that there could ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... Acquisition of Remainder of NexGen Diagnostics Captures Promising ... Intellectual ... BEC ), a leading developer of products that simplify and,automate complex ... acquire the remaining 80.1 percent of NexGen,Diagnostics LLC, a spin out ...
... Marks & Co. LP has partnered,with BlueStar Capital Management ... LP. The partnership also gives Carl Marks a stake ... and an,increased presence in the healthcare investment sector., ... which are,long and short public healthcare equities, in both ...
... announced today,the presentation of the results obtained so far ... and Dr. John Barrett* of the National,Heart, Lung, and ... Health (NIH) on Kiadis, lead product ATIR at the ... According to the NHLBI investigators the challenge in the ...
Cached Biology Technology:Beckman Coulter to Acquire Exclusive Rights to Break-Through Technologies 2Carl Marks Seeds New Healthcare Fund Through Strategic Partnership With BlueStar Capital Management 2Promising Data ATIR Studies Presented by NIH Investigators 2
... dUTPase The thermostable dUTPase(pyrococcus ... PCR (using proofreading DNA polymerases). ... PCR reactions and dNTP solutions. ... proofreading DNA polymerase reaction can prevent ...
... an exciting product for cell-based kinetic assays ... the use of expensive HTS equipment, which ... the assay development stage. The NOVOstar offers ... as well as any other assay suitable ...
... save space and organize gloves, ... other garb. They are the ... small parts used in labs, ... Open-slot design for easy cleaning. ...
... Agilent Technologies introduces an enhanced ... ICP-MS for Windows 2000 and ... From September 2003, all new ... controlled by the new ChemStation ...
Biology Products: